Bokern, M. ., Rentsch, C. T., Quint, J. K., Hunnicutt, J. ., Douglas, I. ., & Schultze, A. . (2025). Using Quantitative Bias Analysis to Adjust for Misclassification of COVID-19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID-19 Outcomes. Pharmacoepidemiol Drug Saf, 34, e70086. http://doi.org/10.1002/pds.70086
pharmacoepidemiology
Mansi, E. T., Rentsch, C. T., Bourne, R. S., Jeffery, A. ., Guthrie, B. ., & Lone, N. I. (2025). Benzodiazepine and z-drug prescribing in critical care survivors and the risk of rehospitalisation or death due to falls/trauma and due to any cause: a retrospective matched cohort study using the UK Clinical Practice Research Datalink. Intensive Care Med, 51, 125–136. http://doi.org/10.1007/s00134-024-07762-4
Persson, R. ., Hagberg, K. W., Pranschke, E. ., Vasilakis-Scaramozza, C. ., & Jick, S. . (2024). Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink. Osteoporos Int. http://doi.org/10.1007/s00198-024-07262-7
Baptiste, P. J., Wong, A. Y. S., Schultze, A. ., Clase, C. M., Leyrat, C. ., Williamson, E. ., … Wing, K. . (2024). Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Am J Epidemiol. http://doi.org/10.1093/aje/kwae137
Schultze, A. ., Martin, I. ., Messina, D. ., Bots, S. ., Belitser, S. ., Carreras-Martínez, J. ., … Douglas, I. . (2024). A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases. Vaccine, 42, 3039–3048. http://doi.org/10.1016/j.vaccine.2024.03.043
Shapiro, S. B., Yin, H. ., H. Y. Yu, O. ., & Azoulay, L. . (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
Eroglu, T. E., Coronel, R. ., & Souverein, P. C. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvae022
Pradhan, R. ., H. Y. Yu, O. ., Platt, R. W., & Azoulay, L. . (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ Open Diabetes Res Care, 11. http://doi.org/10.1136/bmjdrc-2023-003550
Jödicke, A. M., Tan, E. H., Robinson, D. E., Delmestri, A. ., & Prieto-Alhambra, D. . (2023). Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom. Age Ageing, 52. http://doi.org/10.1093/ageing/afad177
van Hulten, V. ., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R. ., Klungel, O. H., … van den Bergh, J. P. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220